Both ARBs and ACEIs were designed to treat hypertension by reducing signaling of the angiotensin II peptide hormone via the angiotensin II type-1 receptor (AT1R), but they differ in how they achieve the reduction in angiotensin II, and may differentially affect processes related to AD [3, 27]. Here, AGT is linked to Hypertension.